Hydrolysis of N-glycans under Native Conditions using PNGase F

Application

Complete Fc N-glycan removal under native conditions, enabling simplfied subunit LC-MS analysis of therapeutic antibodies.

The Fc N-glycans play a crucial role in the effector function of antibodies but may add complexity to protein characterization assays. Removing the Fc N-glycan with PNGase F under native conditions enables characterization of both the free N-glycan and the function and structure of the deglycosylated antibody.

To demonstrate the efficient removal of Fc N-glycans by PNGase F Immobilized and PNGase F Lyophilized under native reaction conditions, the therapeutic antibody trastuzumab was first digested using FabRICATOR. The scFc, LC and Fd’ subunits were then reduced before Fc N-glycan removal using the different formats of PNGase F for 1 h at 37°C. The observed mass shift demonstrates successful removal of the Fc N-glycans.

Efficient removal of all N-glycan types from human IgG

We can observe a large PNGase F peak eluting just before 7 minutes in the sample deglycosylated using PNGase F Lyophilized. A peak such as this could potentially mask a critically important protein variant. This peak is minimized in the sample digested with PNGase F Immobilized, highlighting a benefit of this format to reduce the amount of enzyme interfering in the final sample.

Complete deglycosylation with reduced enzyme in final sample using PNGase F Immobilized

When using either PNGase F Lyophilized or Immobilized, we can observe in the mass spectra that complete deglycosylation has occurred leaving behind only the protein component. This allows the deglycosylated mass of the protein portion of the scFc to be determined an also allows more confident characterization of any protein modifications that might be present, which would not be as easy to do, if at all, when the glycans are present due to the increased sample heterogeneity.

Reduced heterogeneity for simplified characterization of therapeutics

Total Ion Chromatogram (top) and deconvoluted mass spectra (bottom) of the scFc fragment of trastuzumab treated with PNGase F or PNGase F Immobilized under native reaction conditions. Trastuzumab was incubated for 1 h with PNGase F Immobilized using native reaction conditions or PNGase F Lyophilized for 1 h at 37°. The deglycosylated antibodies were digested with FabRICATOR, reduced and analyzed by reversed-phase LC-MS on a Waters™ BioAccord™ system equipped with a Waters™ BioResolve™ RP mAb column (2.1 x 50 mm). The TIC chromatogram clearly shows the absence of the PNGase F enzyme in the sample treated with PNGase F Immobilized.

Related Products

Resources